AST/IDSA Webinar: COVID-19 Vaccine in Transplant & Immunocompromised Populations - Shared screen with speaker view
What is the rate of Ab positivity using these assays after 1 dose of m
RNA vaccine in non-transplant patients?
Please use the Q&A box to ask your question.
I have a BMT patient presneted with graft, liver and kidney failure, 2 weeks post first dose of Moderna vaccine. We can't prove causation for sure, my question, when to reconsider the second dose, knowing the the Moderna vaccine is dosed higher than Pfizer vaccine? Thank you
Please ask your question using the Q&A box.
AST Resources:https://www.myast.org/covid-19-vaccine-faq-sheethttps://www.myast.org/covid-19-informationCOVID-19 Real-Time Learning Network:www.COVID19LearningNetwork.orgVaccine FAQ:https://www.idsociety.org/covid-19-real-time-learning-network/vaccines/vaccines-information--faq/@RealTimeCOVID19#RealTimeCOVID19
Judith M. Harris, LCSW
Thank you all! Excellent presentation.
ASCO/IDSA Global Webinar: COVID-19 Vaccines and Cancer CareTo Register: https://asco1.zoom.us/webinar/register/WN_B5a0zz4JR1yqdb4zseu6jARecordings of this call will be posted on:www.idsociety.org/cliniciancallswww.myAST.org/covid